Evaluation of antifungal therapy in patients with candidaemia based on susceptibility testing results: implications for antimicrobial stewardship programmes

被引:60
作者
Shah, D. N.
Yau, R.
Weston, J.
Lasco, T. M.
Salazar, M.
Palmer, H. R.
Garey, K. W. [1 ]
机构
[1] Univ Houston, Coll Pharm, Houston, TX 77030 USA
关键词
Candida; echinocandins; fluconazole; INFECTIOUS-DISEASES-SOCIETY; CANDIDEMIA; FLUCONAZOLE; MORTALITY; TIME; CANDIDIASIS; GUIDELINES; MANAGEMENT; SURVEILLANCE; AMERICA;
D O I
10.1093/jac/dkr244
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Definitive antifungal therapy is typically based on Candida species and clinical status, rather than susceptibility reports. Antifungal susceptibility testing is available, but the impact on treatment decisions is unknown. The purpose of this study was to assess antifungal therapy in hospitalized patients with candidaemia during the time period between the start of empirical therapy and after antifungal susceptibility testing reports are available. Methods: A retrospective study of 161 hospitalized patients with candidaemia was conducted. Patients who received fluconazole or an echinocandin were evaluated for changes in empirical antifungal therapy prior to and after susceptibility reporting. Results: One hundred and sixty-one patients aged 59 +/- 16 years (male, 54%; Caucasian, 52%; APACHE II score >= 15, 48%; and intensive care unit, 50%) were identified, of whom 130 (81%) had fluconazole-susceptible candidaemia. Fifty-eight patients (36%) were initiated on fluconazole and 103 (64%) on an echinocandin. The mean time from culture to the susceptibility report was 5 +/- 2 days. Prior to availability of the susceptibility report, 20 fluconazole-initiated patients (34%) were switched to an echinocandin, while 14 echinocandin-initiated patients (14%) were switched to fluconazole. Once a susceptibility report was available, 35 of 89 (39%) patients with fluconazole-susceptible candidaemia on an echinocandin were de-escalated to fluconazole. Eleven patients on fluconazole just prior to a susceptibility report were identified with a fluconazole-resistant Candida species. Conclusions: Using antifungal susceptibility testing, patients given fluconazole with fluconazole-resistant Candida species were identified. Less than 40% of echinocandin-treated patients with fluconazole-susceptible organisms were de-escalated to fluconazole. Antifungal susceptibility testing may help to identify patients in need of clinical intervention.
引用
收藏
页码:2146 / 2151
页数:6
相关论文
共 15 条
[1]   Comparison of risk factors for candidemia versus bacteremia in hospitalized patients [J].
Amrutkar, P. P. ;
Rege, M. D. ;
Chen, H. ;
LaRocco, M. T. ;
Gentry, L. O. ;
Garey, K. W. .
INFECTION, 2006, 34 (06) :322-327
[2]   Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia [J].
Baddley, JW ;
Patel, M ;
Jones, M ;
Cloud, G ;
Smith, AC ;
Moser, SA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 50 (02) :119-124
[3]   Role of antifungal susceptibility testing in patient management [J].
Forrest, Graeme .
CURRENT OPINION IN INFECTIOUS DISEASES, 2006, 19 (06) :538-543
[4]   Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Diseases Society of America (IDSA) guidelines [J].
Garey, Kevin W. ;
Pai, Manjunath P. ;
Suda, Katie J. ;
Turpin, Robin S. ;
Rege, Milind D. ;
Mingo, Dana E. ;
Bearden, David T. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (08) :919-927
[5]   Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study [J].
Garey, Kevin W. ;
Rege, Milind ;
Pai, Manjunath P. ;
Mingo, Dana E. ;
Suda, Katie J. ;
Turpin, Robin S. ;
Bearden, David T. .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (01) :25-31
[6]   Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients [J].
Hadley, S ;
Martinez, JA ;
McDermott, L ;
Rapino, B ;
Snydman, DR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) :415-419
[7]   The role of antifungal susceptibility testing in the therapy of candidiasis [J].
Hospenthal, DR ;
Murray, CK ;
Rinaldi, MG .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2004, 48 (03) :153-160
[8]   Current status and future perspectives on molecular and serological methods in diagnostic mycology [J].
Lau, Anna ;
Chen, Sharon ;
Sleiman, Sue ;
Sorrell, Tania .
FUTURE MICROBIOLOGY, 2009, 4 (09) :1185-1222
[9]   Excess mortality, hospital stay, and cost due to candidemia: A case-control study using data from population-based candidemia surveillance [J].
Morgan, J ;
Meltzer, MI ;
Plikaytis, BD ;
Sofair, AN ;
Huie-White, S ;
Wilcox, S ;
Harrison, LH ;
Seaberg, EC ;
Hajjeh, RA ;
Teutsch, SM .
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2005, 26 (06) :540-547
[10]   Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained:: a potential risk factor for hospital mortality [J].
Morrell, M ;
Fraser, VJ ;
Kollef, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (09) :3640-3645